Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
718.36
-4.44 (-0.61%)
At close: Dec 5, 2025, 4:00 PM EST
721.00
+2.64 (0.37%)
After-hours: Dec 5, 2025, 7:45 PM EST
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.75B in the quarter ending September 30, 2025, with 0.90% growth. This brings the company's revenue in the last twelve months to $14.25B, up 2.89% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.25B
Revenue Growth
+2.89%
P/S Ratio
5.33
Revenue / Employee
$943,188
Employees
15,106
Market Cap
73.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
REGN News
- 2 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 5 days ago - Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? - The Motley Fool
- 11 days ago - Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) - GlobeNewsWire
- 11 days ago - Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria - GlobeNewsWire
- 11 days ago - 1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month - The Motley Fool
- 14 days ago - This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead - Investopedia